CLINICAL TRIALS

TRC105

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Recruiting Advanced angiosarcoma A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazoapnib Alone in Patients with Advanced Angiosarcoma (TAPPAS) Phase 3 TRC105 + Votrient® (Pazopanib) NCT02979899
Ongoing, not recruiting Advanced Renal Cell Cancer A Randomized Phase 2 Trial of Axitinib and TRC105 versus Axitinib Alone (including a lead-in Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma Ph 1b/2b randomized TRC105 + Inlyta® (axinitib) NCT01806064
Ongoing, not recruiting Advanced Soft Tissue Sarcoma A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Ph 1b/2a TRC105 + Votrient® (Pazopanib) NCT01975519
Recruiting Hepatocellular Carcinoma An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC) Ph 1b/2a TRC105 + Nexavar® (sorafenib) NCT02560779
Recruiting Non-Squamous Cell Lung Cancer Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme Ph 1b TRC105 + Avastin® (bevacizumab) + Paclitaxel/Carboplatin NCT02429843
Recruiting Non-Small Cell Lung Cancer A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer Phase 1b TRC105 + Opdivo® (nivolumab) NCT03181308
Recruiting Breast Cancer A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer Ph 1/2 TRC105 + Femara® (letrozole) + Afinitor® (everolimus) NCT02520063
Recruiting Gestational trophoblastic neoplasia A Phase 2A Study of TRC105 (With Option to Add Standard Dose Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Phase 2 TRC105 or TRC105 + Avastin® (bevacizumab) NCT02664961

TRC102

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Ongoing, not recruiting Recurrent Glioblastoma Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma Phase 2 TRC102 + Temodar® (temozolomide) NCT02395692
Recruiting Non-squamous Non-small Cell Lung Cancer A Phase I Study of Methoxyamine Combined With Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer Phase 1 TRC102 + Chemoradiation NCT02535325
Recruiting Advanced Solid Tumors or Mesothelioma Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed Ph 1b/2 TRC102 + Alimta® (pemetrexed) + cisplatin; TRC102 + Alimta NCT02535312
Recruiting Solid tumors (oral) TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Ph 1b TRC102 + Temodar® (temozolomide) NCT01851369

TRC253

TUMOR TYPE STUDY PHASE AGENT(S) INFORMATION
Recruiting Metastatic castration-resistant prostate cancer (mCRPC) A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Phase 1/2a TRC253 NCT02987829